Donate
Return to Map
Return to Map

California Bladder Cancer Resources

California Department of Public Health
http://cdph.ca.gov/

Contact Your State Elected Representative

Bladder Cancer Cases in California at a Glance

  • 7,330

    New State Cases
     

  • 83,190

    New National
    Cases

  • 63,070

    National Cases in Men

  • 20,120

    National Cases in Women

  • 16,840

    National Deaths
     

NCI-Designated Cancer Centers and NCCN Member Institutions

The National Cancer Institute, (NCI) has recognized Cancer Centers for delivering cutting-edge cancer treatments to patients in communities across the United States. There are 71 NCI-Designated Cancer Centers, located in 36 states and the District of Columbia, that are funded by NCI to deliver cutting-edge cancer treatments to patients. Most of the NCI-Designated Cancer Centers are affiliated with university medical centers, although several are freestanding institutions that engage only in cancer research.

The National Comprehensive Cancer Centers (NCCN) are a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

  • NCI Designated Comprehensive Cancer Centers
  • National Comprehensive Cancer Network Member Institution
City of Hope Comprehensive Cancer Center

Duarte, CA
626-256-4673
Jonsson Comprehensive Cancer Center

Los Angeles, CA
310-825-5268
Moores Comprehensive Cancer Center

La Jolla, CA
866-773-2703
Salk Institute Cancer Center

La Jolla, CA
858-453-4100
Sanford Burnham Prebys Medical Discovery Institute

La Jolla, CA
858-646-3100
Stanford Cancer Institute

Stanford, CA
650-736-6170
UC Davis Comprehensive Cancer Center

Sacramento, CA
916-734-5959
UC San Diego Moores Cancer Center

La Jolla, CA
858-822-6100
UCLA Jonsson Comprehensive Cancer Center

Los Angeles, CA
310-825-5268
UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, CA
888-689-8273
USC Norris Comprehensive Cancer Center

Los Angeles, CA
323-865-3000

Veterans Administration Hospitals

Central California VA Health Care System
Livermore
Menlo Park
San Francisco VA Health Care System
VA Loma Linda Healthcare System
VA Long Beach Healthcare System
VA Palo Alto Health Care System
VA San Diego Healthcare System

Bladder Cancer Clinical Trials in California

Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
See more clinical trials

Read Our Stories